Search PubMed⌕ Search

Biomedical subjects

R Bataille

Publications and source records attributed to R Bataille.

At least 235 records · Page 13Linked to original sources
PubMed1981

[Serum beta-2-microglobulin in multiple myeloma. Practical value].

The concentration of serum, beta-2-microglobulin (S beta 2m) and the ratio measured S 2m/theoretical S beta 2m M/TH were evaluated in 69 patients with multiple myeloma (MM) and compared with healthy subjects and with patients with a benign monoclonal gammapathy. The concentration of S beta 2m and the ratio S beta 2m M/TH are higher in multiple myeloma than in controls and are strongly correlated with the plasma cell mass On the other hand, no difference was noted concerning the S beta 2m and the ration S beta 2m M/TH between benign monoclonal gammopathy and multiple myeloma at stage I of Durie and Salmon. Under chemotherapy, the variations in concentrations of S beta 2m and of the ratio S beta 2m M/TH are strongly correlated with those of the tumour mass. Beta 2m is not very useful for the differential diagnosis between benign monoclonal gammapathy and multiple myeloma. Beta 2m is very useful in the prognosis of MM, permitting one to assess accurately the tumour mass and the response to treatment, particularly in cases of deficiency of the usual markers.

Beta-Globulins↗
PubMed1981

[Effect of the manner of the response to chemotherapy on the prognosis of myeloma. Preliminary study].

The tumor mass regression following the first course of treatment (T1), the time to greater than or equal to 50% tumor regression (TR 50%) and the time to maximum regression (t) were assessed in 29 out of 55 multiple myelomas (MM) successfully treated with alkylating agents. According to t, TR 50% and T1 values, 3 distinctive categories of responsive patients were separated: 1) fast responsive patients (= t less than or equal to 2 months, 48% of cases); 2) intermediate responsive patients (= 3 less than t or 12 months, 38%); 3) and slow responsive patients (= t greater than 12 months, 14%). The first remission duration was shown to be highly related to t (p less than .001), TR 50% (p less than .01) and T1 (p less than .05), the shortest remissions being observed in fast responsive patients. In relapse, the tumor doubling time (TD) was correlated with t, TR 50% and T1 (p = .05), the shortest TD being observed in fast responsive patients. It was shown that pure Bence-Jones and hypercalcemic myelomas were the fastest responsive patients.

Aged↗
PubMed1980

Myeloma bone marrow acid phosphatase staining: a correlative study of 38 patients.

Acid phosphatase (AP) activity of plasma cells was studied in 38 patients with multiple myeloma (MM). The average activity per cell was strong (mean score = 2.42; maximum score = 4) and the percentage of positive cells was greater than 90% in over 71% of patients. The average AP activity per cell was higher prior to treatment (3.06 +/- 0.53) compared to relapse (2.48 +/- 0.77) and remission (1.81 +/- 1.02 (p less than 0.05 and p less than 0.01, respectively). In correlation of AP activity with clinical features at the time of the study, the only significant difference was between kappa and lambda subtype. Patients with lambda MM had a higher average AP activity per cell in remission (2.71 +/- 0.43) as opposed to kappa MM (1.17 +/- 1.06, p less than 0.05 for difference). AP activity was not significantly correlated with degree of bone involvement. However, activity seemed to be a good marker of disease activity.

Acid Phosphatase↗
PubMed1980

[Rapidly progressing basal-cell naevi (author's transl)].

Basal-cell epitheliomas are of primary importance when discussing a case of multiple naevi. Two factors have to be considered to explain therapeutic failures: --Firstly, the very active local malignancy of these basal-cell epitheliomas; --Secondly, the long delay in applying drastic treatment such as wide excision and immediate repair, and the danger arising from divergent therapy because of lack of a common decision between the various specialists concerned: dermatologist, ophthalmologist, radiotherapist, and plastic or maxillofacial surgeon.

Adult↗
PubMed1980

[Value of successive chemotherapy in multiple myeloma of bone. Prospective study over 4 years].

In order to study the response of patients with multiple myeloma of the bones (MM) to various anti-cancer drugs (Melphalan M, Cyclophosphamide Cy, Nitrosourea NU, Vincristine V, Adriamycine A and Prednisone P), 70 MM received the following treatment : 1) Induction therapy : a) M and P or b) M and Cy and P ; 2) Levelling with partial or complete response : V Cy P (in case a) or V M Cy P (in case b) ; 3) Relapse : A and NU. The following results were obtained : 1) Only 42.6% of patients respond to induction therapy ; 2) Fewer than 10% of patients showing a response reach a second levelling with Vincristine ; 3) 50% of those not showing a response reach a levelling between --20 and --50 and have prolonged survival ; 4) Only 20% of non responders are improved by Cy P or A and NU. The median actuarial survival is 42 months. Among the responders two poor prognosis factors must be underlined : hypercalcemia and the speed of response.

Aged↗
PubMed1979

[Prostatic osteosis. Retrospective study of 110 cases treated with high-dose estrogens].

On the basis of 110 prostatic osteoses that were histologically proven, constantly painful and demonstrated by X-ray, treated by early estrogenotherapy using very high doses, backed up by a high-dose maintenance estrogenotherapy, the authors study the clinical, radiological, histological and biological profile of this metastatic cancer, as well as the response to treatment. The median actuarial survival time of the patients studied is 18.5 months. No statistically significant prognostic correlation was found. Only patients who are clinically estrogen-sensitive, are suffering from bone metastases without a combined visceral conditions, and have a normal initial rate of alcaline phosphates, tend to have a better prognosis (median actuarial survival 31 months versus 18.5 months for the overall population).

Adult↗
PubMed1979

[Multiple myeloma of bones. Retrospective study of prognostic factors based on a series of 243 patients].

The authors have made a retrospective study of 243 cases of multiple myelomas, most of them treated with alkylating agents. The average age at the time of diagnosis was 65 years (+ 10). The ratio of the sexes was 1 : 1. Seventy two per cent of the patients had a bone rating of 2 or 3 according to the criteria of Durie and Salmon. Fifty-eight per cent of the patients were anemic (Hg 12 g per cent), with less than 15 per cent being leucopenic or thrombopenic. Hypercalcemia (105 mg 0/00) was noted in 27 per cent of cases. The distribution of immunochemical types is as follows : IgG, 51.5 per cent; IgA, 28 per cent; pure Bence Jones, 20.5 per cent. The respective percentages of kappa and lambda light chains were 64.2 per cent and 35.8 per cent. In this series, nearly 80 per cent of the patients were at phase III according to the classification of Durie and Salmon, and 30.8 per cent at phase B. The median survival, including all phases, increased from 8 months without alkylating agent, to 20 months with melphalan and/or cyclophosphamide. The factors influencing the survival of the patients treated were age, the hemoglobin level, calcemia, renal deficiencies, the immunochemical type, the stage of the disease, and the response to alkylating treatment. The value of these different prognostic factors is discussed.

Adult↗
PubMed1978

[Evaluation of the tumor mass and its regression under treatment of multiple myeloma of the bones. Critical comments apropos of 22 patients].

In reference to 22 recent cases of multiple myeloma the authors underline the value of estimating the tumour size and its variations under treatment, according to the method of Salmon and Durie. This allows an estimation of the initial prognosis and rapide evaluation of the response to treatment given, permitting a truly strategic approach to the treatment of multiple myeloma.

Bone Neoplasms↗
PubMed1978

[Lysis of the odontoid process in rheumatoid polyarthritis].

The authors report 9 cases of partial or total lysis of the odontoid peg in rheumatoid arthritis. Retrospective study of 100 cases of rheumatoid arthritis and the data from the literature demonstrate the rarity of these lesions, the last stage of the odontoid erosions which are much commoner. The therapeutic approach is usually nuero-surgical.

Aged↗
PubMed1977

[Associated and secondary chondrocalcinosis].

The authors consider the problems posed by secondary and associated chondrocalcinosis (CCA) on the basis of a study carried out at many French Rheumatology centres (Centres de Rhumatologie Française) and in the light of data in the literature. CCA is associated with gout in 4 percent of cases, with hyperparathyroidism in 3.9 percent of cases, with haemochromatosis in 1.7 percent of cases and with hypothyroidism in 0.8 percent of cases. The existence of secondary CCA in gout, hyperparathyroidism, haemochromatosis, Wilson's disease, ochronosis, hypophosphatasia and perhaps hypothyroidism seems proven. These secondary cases of CCA represent 10.7 percent of the total 1226 : here CCA seems to form one element of a much broader syndrome, namely the metabolic arthropathies. The other associations, with the exception of those which are not considered in this paper (rheumatoid polyarthritis, diabetes mellitus, Paget's disease, osteochrondromatosis, acromegalia), are probably coincidental.

Arthritis, Rheumatoid↗